

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 May 2018 (03.05.2018)



(10) International Publication Number
WO 2018/080916 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 25/28* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/US2017/057564

(22) International Filing Date:
20 October 2017 (20.10.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/412,867 26 October 2016 (26.10.2016) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor; and

(71) Applicant (for US only): AMERIKS, Michael K.
[US/US]; 3210 Merryfield Row, San Diego, California
92121 (US).

(72) Inventors: AMERIKS, Michael K.; 3210 Merryfield
Row, San Diego, California 92121 (US). LAFORTEZA,
Brian Ngo; 3210 Merryfield Row, San Diego, Califor-
nia 92121 (US). LEBOLD, Terry Patrick; 3210 Mer-
ryfield Row, San Diego, California 92121 (US). RAVU-
LA, Suchitra; 3210 Merryfield Row, San Diego, California
92121 (US). SAVALL, Brad M.; 9512 Ronda Avenue, San
Diego, California 92123 (US). SHIREMAN, Brock T.;
3210 Merryfield Row, San Diego, California 92121 (US).

(74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON &
JOHNSON, One Johnson & Johnson Plaza, New
Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS



(57) Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof. Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

WO 2018/080916 A1